A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stemcell-transplantation in patients with high-risk acute leukemia  

作　　者：Qiu-bai LI Lei LI Yong YOU Zhi-chao CHEN Ling-hui XIA Ping ZOU 

机构地区：[1]Institute of Hematology, Union Hospital, Tongl'i Medical College, Huazhong Medical University of Science and Technology, Wuhan430022, China

出　　处：《Acta Pharmacologica Sinica》2009年第10期1471-1478,共8页中国药理学报（英文版）

摘　　要：Aim： To analyze the results of idarubicin （IDA）- versus etoposide （VP16）-intensified myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation （alIo-SCT） for high-risk acute leukemia. Methods： From January 2005 to June 2008, 48 consecutive patients （male： n=29; median age： 30 years, range 14-51 years） with high-risk acute leukemia underwent alIo-SCT following an IDA- or VP16-intensified conditioning regimen. The conditioning regimens were modified BUCY2 （busulfan＋cyclophosphamide） consisting of IDA （15 mg/m2 per day, days -12 to -10） or VP16 （25 mg/kg per day, days -3 to -2） and CY/TBI （cyclophosphamide/total body irradiation） intensified with IDA （15 mg/m2 per day, days -6 to -5） or VP16 （25 mg/kg per day, days -3 to -2） for acute myeloid leukemia and acute lymphoblastic leukemia, respectively. Results： Between the two groups, no significant differences in terms of baseline characteristics, incidence of acute or chronic graft- versus-host disease （GVHD） or transplant-related mortality （TRM） （P=O.50） were observed. However, the IDA group demonstrated higher incidences of mucositis and Aspergillus pneumonia （P〈O.01 and P=O.03, respectively）. For the IDA and VP16 groups, relapse rates were 28% and 50%, respectively （P=0.13）. For the same groups, the 2-year probabilities of leukemia-free survival （LFS） and overall survival （OS） were 72% versus 51% （P=O.04） and 74% versus 53% （P=O.04）, respectively. Conclusion： This retrospective analysis suggests that conditioning regimens intensified with IDA can achieve better outcomes than conditioning regimens with VP16 in patients preparing to undergo alIo-SCT for high-risk acute leukemia.Aim： To analyze the results of idarubicin （IDA）- versus etoposide （VP16）-intensified myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation （alIo-SCT） for high-risk acute leukemia. Methods： From January 2005 to June 2008, 48 consecutive patients （male： n=29; median age： 30 years, range 14-51 years） with high-risk acute leukemia underwent alIo-SCT following an IDA- or VP16-intensified conditioning regimen. The conditioning regimens were modified BUCY2 （busulfan＋cyclophosphamide） consisting of IDA （15 mg/m2 per day, days -12 to -10） or VP16 （25 mg/kg per day, days -3 to -2） and CY/TBI （cyclophosphamide/total body irradiation） intensified with IDA （15 mg/m2 per day, days -6 to -5） or VP16 （25 mg/kg per day, days -3 to -2） for acute myeloid leukemia and acute lymphoblastic leukemia, respectively. Results： Between the two groups, no significant differences in terms of baseline characteristics, incidence of acute or chronic graft- versus-host disease （GVHD） or transplant-related mortality （TRM） （P=O.50） were observed. However, the IDA group demonstrated higher incidences of mucositis and Aspergillus pneumonia （P〈O.01 and P=O.03, respectively）. For the IDA and VP16 groups, relapse rates were 28% and 50%, respectively （P=0.13）. For the same groups, the 2-year probabilities of leukemia-free survival （LFS） and overall survival （OS） were 72% versus 51% （P=O.04） and 74% versus 53% （P=O.04）, respectively. Conclusion： This retrospective analysis suggests that conditioning regimens intensified with IDA can achieve better outcomes than conditioning regimens with VP16 in patients preparing to undergo alIo-SCT for high-risk acute leukemia.

关 键 词：high-risk acute leukemia allogeneic stem cell transplantation intensified conditioning regimen IDARUBICIN ETOPOSIDE 

分 类 号：Q344.13[生物学—遗传学] TQ464.9[化学工程—制药化工]